By Fineline Cube Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.
Regulatory Milestone
| Parameter | Details |
|---|---|
| Companies | Daiichi Sankyo (TYO: 4568) and Merck & Co. (NYSE: MRK) |
| Drug | Ifinatamab deruxtecan (I-DXd) |
| Application Type | Biologics License Application (BLA) |
| Regulatory Status | Accepted with Priority Review |
| Indication | Extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy |
| PDUFA Date | October 10, 2026 |
| Classification | Potential first-in-class B7-H3 directed DXd antibody drug conjugate |
Drug Profile & Innovation
- Technology Platform: Specifically engineered B7-H3 directed DXd antibody drug conjugate (ADC)
- Discovery Origin: Discovered by Daiichi Sankyo, jointly developed with MSD
- Target: B7-H3 (CD276) – immune checkpoint protein overexpressed in multiple solid tumors including SCLC
- Payload: DXd (deruxtecan) – topoisomerase I inhibitor with high potency and bystander effect
- First-in-Class Potential: Would be the first B7-H3 directed ADC approved for any indication if successful
- Unmet Need: Addresses critical gap in ES-SCLC treatment where options are limited after platinum failure
Clinical Evidence Base
Primary Supporting Trial: IDeate-Lung01 Phase 2
- Patient Population: ES-SCLC patients with disease progression after platinum-based chemotherapy
- Primary Endpoint: Objective response rate (ORR) and duration of response (DoR)
- Key Results: Demonstrated clinically meaningful anti-tumor activity with manageable safety profile
Supporting Data: IDeate-PanTumor01 Phase 1/2
- Design: Multi-tumor basket trial evaluating I-DXd across various B7-H3 expressing cancers
- Contribution: Provided additional safety data and confirmed target engagement across tumor types
- SCLC Cohort: Reinforced efficacy signals observed in the dedicated lung cancer trial
Strategic Implications
Market Opportunity
- ES-SCLC Burden: Approximately 30,000 new cases annually in the US with poor prognosis post-platinum
- Treatment Gap: Limited effective options after first-line therapy failure create premium positioning opportunity
- B7-H3 Target Validation: Success would validate B7-H3 as a therapeutically relevant target across oncology
- ADC Leadership: Strengthens Daiichi Sankyo’s position as ADC technology leader alongside Enhertu franchise
Commercial Strategy
- Pricing Power: First-in-class status and unmet need support premium pricing
- Market Access: Priority Review designation may accelerate payer coverage decisions
- Global Expansion: US approval would facilitate regulatory submissions in EU, Japan, and other major markets
- Pipeline Catalyst: Success could accelerate development in other B7-H3 expressing tumors including prostate, ovarian, and pediatric cancers
Competitive Landscape
- Current Standard: Limited options include topotecan, lurbinectedin, and clinical trials
- Differentiation: Novel target (B7-H3) avoids competition with established pathways
- ADC Competition: Distinct from other SCLC ADCs targeting different antigens like DLL3
- Bystander Effect: DXd payload may provide advantage in heterogeneous tumor environments
Next Steps
The companies will prepare for potential commercial launch in Q4 2026, pending FDA approval. Additional regulatory submissions in other geographies are expected to follow the US decision.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approval, commercial expectations, and development plans for ifinatamab deruxtecan. Actual results may differ due to risks including FDA review outcomes, competitive developments, and market acceptance.-Fineline Info & Tech